Recent studies in lymphohemopoietic cells show that transferrin (Tf), a pivotal component of iron transport and metabolism, also exerts cytoprotective functions. We show here in a murine model that Tf interferes with Fasmediated hepatocyte death and liver failure. The mechanism involves the downregulation of apoptosis via BID, cytochrome c, caspase-3 and caspase-9, and upregulation of antiapoptotic signals via Bcl-xL. The results obtained with iron-saturated Tf, Apo-Tf and the iron-chelator salicylaldehyde isonicotinoyl hydrazone indicate that the observed antiapoptotic effect of Tf was not mediated by iron alone. In conclusion, the data suggest that Tf has broader functions than previously recognized and may serve as a cytoprotective agent. Keywords: apoptosis; hepatocytes; fas signaling; transferrin; cytoprotection Transferrin (Tf) is a ubiquitous protein with a central role in iron (Fe) transport and metabolism.
Transferrin (Tf) is a ubiquitous protein with a central role in iron (Fe) transport and metabolism. 1, 2 There is evidence, however, that in addition, Tf has profound effects on cell/cell interactions and cell integrity. [3] [4] [5] We have shown in rodent, canine and human models that Tf interferes with programmed cell death induced via agonistic Fas signals, tumor necrosis factor alpha (TNFa) and gamma-irradiation. 6 The mechanism is not known but the fact that Tf mediated the effects across species barriers suggests a pathway preserved through evolution. In the present study, we used a murine in vivo model of Fas-mediated hepatocyte death 7 to dissect the pathway(s) by which Tf exerts its cytoprotective effects.
The Fas receptor (Fas, APO-1, CD95) is highly expressed in the liver 8 and serves as a central mediator of cell death under physiological and pathological conditions. [9] [10] [11] [12] Ogasawara et al 7 showed in a murine model that the injection of agonistic anti-Fas monoclonal antibody (mAb) within hours resulted in death from liver failure. There is some debate as to whether liver failure is induced via direct effects on hepatocytes or indirectly via endothelial cell injury and hemorrhage into the liver. 13, 14 Our results on the effect of exogenous Tf on Fasmediated hepatocyte death in the Ogasawara model 7 in vivo, and in murine hepatocyte cell lines in vitro, show that Tf interfered with apoptosis, mitigated biochemical liver function abnormalities and prolonged survival in mice treated with otherwise lethal doses of agonistic anti-Fas mAb. The data suggest that Tf exerted its effect via a pathway that involves the upregulation of Bcl-xL and blockade of caspase-9 cleavage.
Materials and methods

Animals
Female BALB/c mice, 2-5 months old were purchased from Charles River (Hollister, CA, USA). Female C57BL/6J mice which were 2 months old, were purchased from Jackson Lab (Bar Harbor, ME, USA). Mice were used with the approval of the Institutional Animal Care and Use Committee and under National Institutes of Health guidelines. was a gift from Dr Ponka (McGill University, Montreal, Canada). Rabbit anti-actin antibody was purchased from Sigma.
Experimental Protocols in Mice
aFas was injected once intraperitoneally (i.p.) in a volume of 0.25 ml at doses ranging from 5 to 25 mg per mouse. Tf was injected i.p. or intravenously (i.v.) repeatedly (two (24 and 1 h before aFas injection) or four times (48, 24 and 1 h before, and 1 h after aFas injection)) in volumes of 0.25 ml at doses of 0.05-1.0 mg/mouse as indicated. Control animals received identical volumes of saline or corresponding doses of HSA preparations i.p. or i.v.
Biochemical Liver Function Parameters
Blood samples were obtained from retro-orbital sinuses of the mice under light halothane anesthesia 3 and 8 h after lethal and nonlethal doses of antiFas mAb, respectively. Aspartate-aminotransferase (AST), alanine-aminotransferase (ALT) and total bilirubin (TBIL) in murine plasma were determined spectrophotometrically at Phoenix Central Laboratory (Everett, WA, USA). Lactate dehydrogenase (LDH) was measured by using LDN-L Tris System Pack (Boehringer Mannheim, Germany) at Ani Lytics Lab (Gaithersburg, MD, USA).
Liver histology
Liver tissue was fixed in 10% formalin and embedded in paraffin. Sections (4 mm) were stained with hematoxylin/eosin, or prepared for terminal deoxynucleotidyl transferase and nick translation end labeling assay (TUNEL) or for immunohistochemical analysis to identify apoptotic hepatocytes in situ. TUNEL staining for determination of individual apoptotic cells 16 was performed with the In Situ Cell Detection Kit according to protocol (Boehringer Mannheim, IN, USA).
Immunohistochemistry for Active Caspase-3
Ex vivo
Tf or saline pretreated mice were killed 3 h after lethal doses of aFas injection, and blood samples and liver tissue were harvested. Formalin-fixed, paraffin-embedded organ sections were stained with rabbit polyclonal antibodies directed at active mouse caspase-3 (Cleaved Caspase-3 Ab, Cell Signaling Technology, #9661). Biotinylated goat antirabbit antibody was added as a second step, and HRP-conjugated streptavidin as a third step. Staining was visualized with DAB/NiCl 2 chromogen. As a negative control, staining was performed without primary antibodies. Immunostaining was quantitatively assessed using a Â 20 optic with a 10 Â 18 ocular with an internal reticule surrounding a field size of 0.26 Â 0.18 mm 2 . The assessed field was determined by placing the portal space, and when present, central vein in the center of the field. At least 10 fields of each slide sample were counted.
In vitro NMH cells were maintained 17 and treated with Tf and anti-Fas MAB as described below. Cells were harvested at different time points after the addition of anti-Fas MAB onto 12-well adhesive slides (Fisher, Pittsburgh, PA, USA), fixed with acetone and stained with purified rabbit polyclonal antibodies directed at active mouse caspase-3 (Pharmingen, cat # 67341A). Biotinylated goat anti-rabbit antibody was added as a second step and HRPconjugated streptavidin as a third step. Staining was visualized with DAB/NiCl 2 chromogen. As a negative control, staining was performed without primary antibodies.
Preparation of Liver Tissue and Proteins
Total body perfusion of euthanized mice via the left ventricle and open right atrium of the heart was performed with phosphate-buffered saline (PBS) to wash out blood from the liver. Slices of liver tissue were then snap-frozen in liquid nitrogen and stored at À70 o C until use. Triton X-100 lysis buffer 18 and Chaps Cell Extract Buffer (Cell Signaling Technology) were used for liver tissue and blood plasma lysate preparation. After centrifugation at 10 000 g for 10 min, the supernatants were kept at À701C until analysis.
Western Blots
Tf Quantitative anti-Tf Western blots were performed with serum albumins and plasma Tf as standards. Proteins separated on gels were transferred onto a PVDF membrane and immunodetected with goat anti-human Tf antibody (Sigma) and secondary alkaline phosphatase-conjugated anti-goat antibody.
Caspase-8 and 10, BID, Bcl-xL, cytochrome c, caspase-9 and caspase-3 Cell and plasma extracts were subjected to SDS gel (12%) electrophoresis and immunoblot analysis. The amount of protein was estimated using BioRad Protein Assay and equal amounts of protein (20-40 mg) were loaded in each lane. The proteins were electrophoretically transferred onto an immunoblot PVDF membrane (BioRad) and blocked with 5% nonfat dry milk in PBS/0.05% Tween-20 (PBS-T) for 1 h at RT. Membranes were incubated with primary antibody diluted in 5% BSA/PBS-T overnight at 41C and washed three times with PBS-T. The blots were then incubated with HRP-conjugated secondary antibody for 1 h at RT in 2.5% BSA/PBS-T. Protein was detected using enhanced chemoluminescence reagents and CL-Xposure film (Pierce, Rockford, IL, USA). Differences in protein expression were determined by Western blot and densitometry analysis using 1.62 NIH Image.
Cell Lines
The nontransformed murine hepatocyte cell line NMH 17 was provided by Dr Nelson Fausto (Department of Pathology, University of Washington, Seattle, WA, USA). NMH cells were maintained in DMEM/F-12 medium (Gibco BRL, Gaithersburg, MD, USA), supplemented with 5 mg/ml insulin, 5 mg/ml Tf, 5 ng/ml selenium (ITS, Sigma, St Louis, MA, USA), 0.04 mg/ml dexamethasone (Sigma), 50 mg/ml gentamycin (Abbott Lab., North Chicago, IL, USA), 120 mg/ml nicotinamide (Sigma) and 20 ng/ml epidermal growth factor (Collaborative Research, Bedford, MA, USA). After passaging and washing, cells were plated at initial concentrations of 1.0 Â 10 5 cells/ml and maintained in the same medium, but without the addition of ITS. On day 2 of culture, human Tf at concentrations ranging from 0.01 to 25 mg/ml or iron chelator (Fe-SIH) at concentrations ranging from 3.2 to 80 mmol were added. After 24 h, 500 ng/ml of aFas was added in the presence of 40 mg/ml of cycloheximide (CHX, Sigma) to induce apoptosis. aFas alone also induced apoptosis in a small portion of NMH cells. The agonistic effect of aFas on NMH hepatocytes was accentuated in the presence of CHX. 19 Cells were harvested at 24 h after the addition of aFas, and the proportion of viable cells was determined by trypan blue dye (Sigma) exclusion. Apoptosis was determined by Annexin V (FITC or PE) staining (Coulter, Corp., Miami, FL, USA) using flow cytometry or by immunocytochemical staining for active caspase-3 expression as described above.
Isolation of mitochondria from NMH cells
Cell disruption by nitrogen cavitations was used as described 20 with some modifications. Briefly, NMH cells were harvested, rinsed twice with PBS and cell pellets were frozen at À70 o C. Cell pellets were then thawed in the mitochondria isolation buffer (1 mM EDTA, 0.25 M sucrose, 10 mM Tris, pH 7.4 and protease inhibitors). Nitrogen cavitation was performed within a pressure vessel at 350-400 psi with 5 min of equilibration time. The resulting suspension was centrifuged twice at 2000 rpm for 5 min, and the spin supernatant was centrifuged at 14 000 rpm to recover the mitochondrial pellet. The postmitochondrial supernatant was used as the cytosol fraction. BID expression in mitochondria and cytosol fractions was determined by Western blotting as described above.
Statistics
Log-rank test (for survival curve) and Student's t-test were applied for statistical analysis using GraphPadPrizm (version 3) software. Data are presented as mean7s.e.
Results
Tf Protects Against Fas-induced Hepatic Failure
A dose of aFas of 0.4 mg/g of body weight induced death within 3-6 h in all BALB/c mice tested. Over this time course, there was a sharp increase in hepatic transaminase levels (AST; ALT) in plasma (Table 1) . BALB/c mice given aFas at doses of 0.07 mg/g of body weight also showed steep increases in blood levels of transaminases and bilirubin (Table 2 ), but recovered and survived. C57BL6 mice showed a smaller increase in transaminase levels in response to nonlethal doses of aFas than did BALB/c mice consistent with a difference in Fas/Fas-ligand activity in these two mouse strains. 21 Tf attenuated transaminase elevations to a greater extent in BALB/c than in C57BL6 mice ( Table 2) .
BALB/c mice given Tf at doses of 0.5 mg/mouse i.p. or i.v. two times (24 and 0.5 h before a lethal dose of aFas) survived twice as long as control mice given saline (data not shown). Murine and human Tf were equally effective, and the effect was independent of the route of Tf administration. As the doses of murine or human Tf were further increased to 1 mg/mouse, and were given 48, 24 and 1 h before as well as 1 h after aFas administration, survival times were progressively prolonged, and 20% of mice recovered and became long-term survivors ( Figure  1a ). Similar prolongation of survival (23.676.9 vs 5.370.3 h in saline-treated controls; Po0.02) was also observed in mice given two different preparations of human (rather than murine) Tf (Sclavo or Sigma) (Figure 1b ). With increasing doses of Tf, blood plasma transaminase levels decreased towards normal, and the number of active caspase-3-expressing cells in the liver was reduced (Table 1) .
It was of note that mice pretreated with one of two HSA preparations (Sigma), intended to serve as controls, also experienced some prolongation of survival (18. Livers of mice receiving lethal doses of aFas and no Tf contained numerous periportal hepatocytes displaying apoptosis with rounding up and condensation of cytoplasm, and nuclear fragmentation. The sinusoids are congested to frankly hemorrhagic with loss of the hepatocyte cord architecture. In contrast, the liver architecture was intact and without hemorrhage, and only rare apoptotic hepatocytes were present in mice pretreated with Tf either in its Apo-or iron-saturated form (Figure 2 ). Plasma AST, LDH and bilirubin levels of Tf-treated mice decreased towards normal (Figure 2 ). Apo-Tf and iron saturated Tf (Fe-Tf) were equally effective.
Tf Reduces Cleavage of BID and Cytochrome c Release, Blocks Caspase-9 and -3 activation and Upregulates Expression of Bcl-xL
Livers of mice treated with aFas and no Tf showed hepatocyte apoptosis as determined by both immunohistochemical staining for active caspase-3 ( Figure 3a ) and TUNEL technique (Figure 3b ). The extent of apoptosis was significantly diminished in animals pretreated with Tf ( Figure 3 , Table 1 ). At this time point (3 h after aFas injection), Western blots of liver tissue lysates from mice given aFas showed decreased levels of full-length caspase-8 and -10. Earlier time points (0.5 and 1.5 h after aFas) showed no significant changes in the expression of these two 'initiator' caspases nor of 'executioner' caspase-3 (Figures 4 and 6 ). Western blots of liver tissue lysates from aFas-treated mice showed decreased levels of full-length BID as well as decreased levels of caspase-9 with the appearance of a typical caspase-9 cleavage product (Figures 5a and 6 ). Control mice treated with Apo-Tf or Fe-Tf showed a slight increase in the amount of full-length BID relative to saline-treated animals without significant changes in caspase-9. Mice given Apo-Tf or Fe-Tf in addition to aFas showed higher levels of BID and intact caspase-9 than did mice treated with aFas Hepatoprotection by transferrin VA Lesnikov et al only, although levels of caspase-9 remained below those seen in mice not given aFas and treated with Apo-Tf or Fe-Tf only (Figure 5a ). The observed changes in BID and caspase-9 were consistent with the pattern of cytochrome c release. Cytochrome c was not detected in the blood plasma of control mice. In contrast, there was an increase of cytochrome c in the blood plasma of aFas-treated animals. Mice treated with Apo-Tf or Fe-Tf in addition to aFas showed only minute amounts (with Apo-Tf) or no cytochrome c at all (with Fe-Tf) in blood plasma (Figure 5b ).
In line with immunohistochemical observations (Figure 3a) , there was a significant reduction in fulllength caspase-3 levels in aFas-treated animals, suggesting cleavage of this 'executioner' caspase. Mice given Apo-Tf or Fe-Tf in addition to aFas showed levels of full-length (noncleaved) caspase-3 considerably higher than that in mice given aFas and saline only (Figures 4, 5a and 6) .
Levels of Bcl-xL were decreased in aFas-treated mice compared to saline-injected controls. The administration of Fe-Tf (but not Apo-Tf) by itself resulted in an increase in Bcl-xL protein expression. There was a striking further increase in Bcl-xL protein levels in mice injected with Apo-Tf or Fe-Tf in addition to aFas (Figures 5a and 6 ).
These findings suggest that the administration of Tf resulted in a resetting of the balance between proand antiapoptotic members of the Bcl-2 family that was altered by Fas-triggered signals.
What is the role of Iron in the antiapoptotic effect of Tf?
In an attempt to define a possible role of iron in the effects of Tf observed in vivo, experiments were carried out on murine hepatocytes in vitro. Tf protected NMH hepatocytes against Fas-mediated cell death (Figure 7a) . aFas increased the proportion of Annexin V-positive NMH cells from a baseline of 5% (range 2-8%) to 15% (range 8-22%). The concurrent presence of Tf reduced the proportion of apoptotic cells by 20-50% (Figure 7b) . Similarly, Tf decreased the activation of caspase-3 ( Figure 8 ). Among NMH cells treated with aFas, 2872% stained for active caspase-3 at 12 h, and 3373% at 24 h after the addition of aFas. In the presence of Tf, these proportions were reduced to 1872% (Po0.02) and 16%7(Po0.01), respectively.
It is of note that Fe-Tf and iron-free Apo-Tf provided protection, although Fe-Tf was less effective ( Figure 9 ). Comparing the means of the average values of Fe-Tf vs Apo-Tf showed a statistically significant difference (5.870.2 vs 4.470.4%, Figure 4 Caspase-8, -10 and -3 expressions in the liver at different times after aFas injection. BALB/c mice were given aFas and treated with Apo-Tf as described in Figure 2 . Mice were killed at 0.5, 1.5 and 3 h after aFas injection. After total body perfusion with saline, liver tissue was collected, frozen and lysed in Chaps buffer. The cell extracts were analyzed by SDS-PAGE and immunodetected with anti-mouse caspase-8, -10 and -3 antibody, respectively. Western blots from one of two similar experiments are shown. There were no significant changes in the expression of full-length caspases under study at 0.5 and 1.5 h after aFas administration; at 3.0 h, the expression of all caspases was reduced in mice given aFas, and the reduction was decreased in mice pretreated with Tf. Figure 5 Tf reduces BID, caspase-9 and -3 cleavage, cytochrome c release, and increases Bcl-xL expression in the liver. BALB/c mice were given aFas and treated with Apo-Tf or Fe-Tf as described in Figure 2 . Mice were killed 3 h after aFas injection. After total body perfusion with saline, liver tissue was collected, frozen and lysed in Chaps buffer. The cell extracts were analyzed by SDS-PAGE and immunodetected with anti-mouse BID, caspase-9, caspase-3, cytochrome c and Bcl-xL antibody, respectively. Blood plasma was treated identically for cytochrome c determination. Western immunoblots of one from four similar experiments are shown. (a) There was a decrease in levels of full-length BID, caspase-9, caspase-3 and Bcl-xL (with the appearance of caspase-9 and -3 cleavage products) in the liver in response to aFas; the decrease was reduced after pretreatment with Tfs. (b) An increase of cytochrome c in blood plasma of mice receiving aFas was prevented or reduced by Tfs.
respectively, Po0.02, n ¼ 5, Student's t-test). The iron-chelator SIH is capable of iron delivery when saturated with Fe (Fe-SIH), 15 bypassing the physiological Tf-receptor (CD-71) pathway. Iron from Fe-SIH is used efficiently by cells to support proliferation. 2 As shown in Figure 9 , Fe-SIH failed to provide an antiapoptotic effect in hepatocytes, consistent with the notion that the observed antiapoptotic properties of Tf were dependent upon the carrier molecule and were not mediated by Fe alone. Furthermore, NMH cells were treated with Tf and aFas in the presence or absence of the anti-CD71 42/6, which completely prevents iron uptake via CD71 Figure 6 Levels of expression of caspase-8, -10, -9 and -3 and BID and Bcl-xL in mouse liver in vivo. BALB/c mice were given aFas and treated with Apo-Tf or Fe-Tf as described in Figure 2 . Mice were killed 3 h after aFas injection. After total body perfusion with saline, liver tissue was collected, frozen and lysed in Chaps buffer. The cell extracts were analyzed by SDS-PAGE and immunodetected with anti-mouse caspase-8 (casp-8), caspase-10 (casp-10), full-length BID (BID), caspase-9 (casp-9), caspase-3 (casp-3) and Bcl-xL antibody, respectively. For each factor, optical density (OD) of the protein signal (determined with 1.62 NIH image) in liver cell lysates from mice receiving saline only served as a reference (1.0). The means7s.e. of four experiments are shown. Levels of all four caspases, BID and Bcl-xL decreased following aFas exposure; the decrease was prevented or reduced after pretreatment with Tfs. Treatment:
o Po0.05; þ Po0.02 vs 'saline'; *Po0.05, **Po0.01 vs 'saline þ aFas'. Figure 7 Tf protects NMH cells against apoptosis induced by aFas. Cells were cultured in triplicate and treated with Tf (0.01-25 mg/ml on day 2 of culture). aFas at a concentration of 500 ng/ml was added 24 h after Tf (and 30 min after 40 mg/ml of cycloheximide (CHX)). Each bar shows the mean7s.e. of four to 20 experiments, *Po0.01, **Po0.001; untr ¼ untreated. (a) Cell viability was assessed by trypan blue exclusion 24 h after aFas. The proportion of dead cells decreased with Tf pretreatment. There was some evidence for a biphasic response to Tf. (b) Apoptotic cells were identified by flow cytometry using Annexin V-staining. The proportion of Annexin V-positive cells in untreated samples served as a reference point. There was a significant reduction in Annexin V-positive cells at Tf concentrations of 1 and 5 mg/ml. As in (a) there was evidence of a biphasic response. Figure 8 Tf pretreatment reduces the proportion of active caspase-3-expressing NMH cells after exposure to aFas. Tf (5 mg/ ml) was added to cultures 24 h prior to CHX þ aFas. After 12 h, cells were harvested, placed on adhesive slides, fixed with acetone and analyzed immunohistochemically for active caspase-3 expression (black staining). Results of one of four similar experiments are shown. Figure 9 Apo-Tf (Tf) and iron saturated Tf (Fe-Tf) but not FeSIH provide cytoprotection against Fas-induced apoptosis in NMH hepatocytes. Cells were cultured in triplicate and treated with human Tf, Fe-Tf (0.01-25 mg/ml) or with iron-saturated salicylaldehyde isonicotinoyl hydrazone (FeSIH, 3.2-80 mmol/ml) on day 2 of culture. aFas at 500 ng/ml was added 24 h after Tf, Fe-TF or FeSIH (and 30 min after 40 mg/ml cycloheximide (CHX)). Cells were harvested 24 h after the addition of aFas, and apoptotic cells were determined by flow cytometry using Annexin V staining (a); results of one of three similar experiments are schematically summarized in (b). The means7s.e. of triplicate cultures are shown; *Po0.05, **Po0.02 vs CHX þ aFas. There was a protective effect of Tf against apoptosis, more so with Apo-Tf than with Fe-Tf. FeSIH showed no protective effect, and results suggest, in fact, an enhancement of apoptosis.
(Trowbridge and Lopez). 39 As shown in Figure 10 , the presence of MAB 42/6 did not interfere with the ability of Tf to protect NMH hepatocytes against Fasinitiated signals. These findings also argue against a role of CD71 in the antiapoptotic effect of Tf.
Modulation of Fas-induced BID Protein Expression by Tf in Murine NMH Hepatocytes
We induced apoptosis in NMH cells by aFas in the absence of CHX (an inhibitor of protein synthesis) to avoid its possible interference with the expression of proteins under study. In whole-cell lysates, Tf inhibited Fas-induced increases in full-length (p22) BID protein expression (Figure 11a ) in a dosedependent manner. As shown in Figure 11b , strong expression of p22 BID in the cytosol of NMH cells was observed at 1, 6, 12 and 24 h after Fas ligation. Tf alone did not significantly modify BID expression, but had a profound effect on Fas-induced changes in p22 BID protein, more striking in mitochondria than in the cytosol fraction. These changes were markedly time dependent. In addition to p22 BID, cleavage products of BID (truncated BID [tBID, p15]) were detectable in mitochondria in minute amounts, decreasing with increasing Tf concentrations at the 12-h time point (Figure 11c ).
Discussion
These studies show a profound protective effect of Tf against Fas-triggered liver cell death similar to that previously demonstrated for lymphohemopoietic cells. 6 The observed cytoprotective effects of Tf did not appear to be iron dependent and were not achievable with iron alone.
Hepatocytes prominently express the death receptor Fas, and Fas-mediated signals can induce severe hepatocyte injury, presumably via apop tosis. 7, 11 Fas ligation activates 'initiator' caspases-8 and -10, which in hepatocytes affect a mitochondrial pathway to maximize Fas-induced apoptosis. 22 Others have shown that BID protein is required for hepatocyte apoptosis and liver failure induced by aFas. 23, 24 BID is generally cleaved in response to Fas, TNFa or TRAIL signaling and thereby converted to its truncated, active form tBID, 25, 26 which induces cytochrome c release and downstream caspase activation. Our results show that Tf modified BID responses to Fas signaling. The fact that we observed predominantly full-length p22 BID (as well as uncleaved caspase-8, -10 and -3) rather than an increase in tBID (or cleaved forms of caspase-8, -10, and -3) in response to death signals was unexpected. The possible reasons for this might be as follows: (1) very low concentrations of the active forms, a fast Figure 10 Anti-CD71 MAB does not block the effects of Apo-or Fe-Tf on Fas-induced cell death in NMH hepatocytes. Hepatocytes were cultured in triplicate and treated with human Apo-or Fe-Tf (5 mg/ml) or with iron-saturated salicylaldehyde isonicotinoyl hydrazone (FeSIH, 80 mmol/ml) added on day 2 of culture. Anti-CD71 MAB (Ab) (42/6, 12 mg/ml) was added 15 min before Tf, FeTf or FeSIH. aFas (500 ng/ml) was added 24 h after Tf, FeTf or FeSIH (and 30 min after 40 mg/ml of cycloheximide (CHX)). Cells were harvested 24 h after the addition of aFas, and dead cells were enumerated using Trypan blue dye exclusion. The means7s.e. of three experiments are shown. The protective effect of Tf persisted in the presence of anti-CD71 MAB. metabolism and low protein stability; (2) the peculiarities of liver tissue damage in response to agonistic anti-Fas MAB: high local proteolytic activity associated with alterations in blood supply, oxidative stress and release of active proteases. In mice, moderate doses of aFas induce neutrophil recruitment, which potentiate liver injury by release of oxidants and proteases; 27 (3) the dose of Jo2 MAB (0.4 mg/g of body weight) was sufficient to kill mice but insufficient to induce extensive protein cleavage to produce sufficient amounts of active proteins to be detectable by the methods used. However, it has been shown in HepG2 cells that even subnanomolar doses of exogenous tBID induce rapid cytochrome c release from mitochondria, 28 and translocation of p22 BID, considered the inactive form of BID, has been described in other models. 28, 29 In Jurkat cells, Fas-mediated apoptosis involves the translocation of full-length p22 BID to the mitochondria, inducing cytochrome c release and cell death in the absence of BID cleavage. 30 Our in vitro data showed that Tf by itself did not significantly modify p22 BID expression in NMH hepatocytes. However, Tf interfered with the action of Fas-mediated signals on the p22 and p15 forms of BID proteins, possibly affecting translocation, cleavage or both ( Figure  11 ). The observed interference of Tf with the expression of BID and Fas-induced activation of caspase-3 is consistent with observations by Yin et al, 23 who showed that BID-deficient mice were highly resistant to Fas-initiated hepatic damage. In the present model, BID was available, but its function was compromised in the presence of Tf. As a consequence, cytochrome c release decreased and caspase-9 cleavage was prevented or reduced. The result was a lack of 'effector' caspase-3 activation and a reduction in apoptosis.
One potential mechanism by which Tf could interfere with the action of BID on cytochrome c release is the modulation of intracellular concentrations of Mg 2 þ . Mg 2 þ mobilization is an early event in Fas-mediated apoptosis in B cells 31 and in glycodeoxycholate-induced apoptosis in rat hepatocytes. 32 An increase in free cytosolic Mg 2 þ facilitates the BID-or Bax-mediated release of cytochrome c from the mitochondria. 31, 33 Thus, binding of Mg 2 þ
by Tf may contribute to the antiapoptotic effects of Tf. In addition to interfering with proapoptotic signals, Tf also enhanced survival signals. The expression of Bcl-xL was increased by Tf ( Figures  4 and 5a) . Tf was previously shown to induce Bcl-2, 34 and Bcl-2 and Bcl-xL are known to be released following phosphorylation of BAD. 35 One pathway leading to BAD phosphorylation is via insulin-like growth factor (IGF)-mediated activation of PI3-kinase and Akt. 36 Weinzimer et al 5 and Storch et al 37 recently showed that Tf is a natural ligand for the IGF binding protein 3 (IGFBP-3) and also binds IGFs. In cell cultures, IGFBP-3 regulates apoptosis in human breast and prostate cancer (PC-3) cells, 5, 38 and the addition of Tf to cultures of PC-3 cells prevented apoptosis induced by IGFBP-3. 5 Preliminary studies in our laboratory show a similar interaction of Tf with IGFBP-3 in normal lymphohemopoietic cells and hepatocytes (unpublished observations).
Iron is essential for cellular functions 2 and it would be conceivable that iron plays a role in the cytoprotective effects of Tf. Previous studies indicated that the antiapoptotic effect of Tf was iron independent. 6 The current results with apo-Tf, Fe-Tf and the iron-chelator SIH support this hypothesis. Furthermore, as noted already, the presence of an anti-CD71 mAb that blocks iron uptake 39 did not interfere with the antiapoptotic effects of Tf in marrow cells 6 nor in NMH hepatocytes ( Figure 10 ). The present observations also offer at least one answer as to why the observed Tf action was not blocked by anti-CD71 mAb. If Tf can function via an IGF/IGFBP3 pathway, the classic Tf receptor would not be required.
The fact that murine and human Tf exerted comparable protective effects on murine hepatocytes may not be surprising, as mouse Tf has 83% homology with human Tf, 40 and both Tfs have very similar physicochemical characteristics. 41 Thus, exogenous Tf conveyed potent antiapototic/ cytoprotective effects against Fas-mediated signals in hepatocytes, and data presented elsewhere indicate that the protective effects of Tf are not restricted to Fas-induced death signals. 6, 42 The mechanism involves interference of Tf with the signal cascade of apoptosis, specifically BID expression, cytochrome c release, caspase-3 and caspase-9 activation and Bcl-xL expression. These data suggest that Tf may be useful as a hepatoprotective agent.
